Please login to create your UC TechAlerts.
Request a new password for
Required
Optimization Of Lead Small Molecule Inhibitors Of Taspase1 For Cancer Therapeutics
Brief description not available
Genomic Destructive CRISPR Guide RNAs
AAV-Based Gene Therapy for Glioblastoma Treatment Using Interferon Cytokines
Enhancing Cancer Immunotherapy with Modified Adaptor Protein and CAR-NK Cell Technology
Next-Generation Monoclonal Antibody Therapy Targeting High-Risk Tumors
Affinity-Matured Anti-Cd72 Nanobodies For Next-Generation CAR-T Immunotherapies
An off-the-shelf dendritic cell-based cancer vaccine
Lung-Targeted Cell-Based Therapies for Inflammatory Disease and Cancer
Innovative T Cell Gene Editing System for Enhanced Cancer Immunotherapy
Dual Modality Radionuclide-Antibody Drug Conjugate for Advanced Prostate Cancer and Multiple Myeloma
Targeting Tumor-Associated Macrophages to Overcome Immunotherapy Resistance
Dual-Antigen Targeting CAR-T Therapy for Acute Myeloid Leukemia (AML)
A Novel In Vivo Genome-Wide CRISPR Screening Platform for Enhancing T Cell Immunotherapies in Solid Tumors
A Novel Approach to Overcome T Cell Exhaustion for Enhanced Anti-Tumor Activity
Novel Anti-HLA-Pan-DP CAR-T cells for Targeted Cancer Immunotherapy
Targeted Immunotherapy for Multiple Myeloma: Novel Mutant CCL27 Binders Targeting CCR10
Precision In Vivo Gene Editing Using Dual-Vector Delivery Systems
Combination Therapy For CNS Lymphoma
Myeloid Differentiation Factor-Expressing Retroviral Vector for Tumor Therapy
Antibody-Based Chemically Induced Dimerizers (AbCIDs)
This novel technology enables refined temporal control of protein-protein interactions that can be used to regulate cell therapies, including CAR T-cells and “cell factories”.
Anti-CD94 Antibodies for Enhanced Immune Response to Cancer Cells
Manufacturing of Homogeneous T Cells using Synthetic Exon/Expression Disruptors (SEEDs)
Novel Neoantigen-Based Peptides and TCR for Cancer Immunotherapy
Antibodies That Stimulate Nk Cell-Mediated Cytotoxicity
Novel compositions and methods for targeted replacement of endogenous T-cell receptor with a chimeric antigen receptor